Drug Pricing

A growing number of states are considering legislation to create prescription drug affordability review boards during the 2019 session. These boards would enable states to set “allowable rates” for certain high-cost drugs identified by the board, similar to the approach states use to regulate utilities or insurance premiums. NASHP released drug affordability review board model […]

Read More
  • State Health Policy Blog

    Montana Explores a New Approach to Regulating Pharmacy Benefit Managers

    State legislatures across the country continue efforts to address the opaque business practices of pharmacy benefit managers (PBMs) to protect consumers and lower prescription drug prices. Montana is taking a new approach by leveraging its insurance department’s regulatory authority over insurance carriers by proposing a bill that tasks insurers with responsibility for overseeing that PBMs […]

    Read More
  • State Health Policy Blog

    Annual Federal Insurance Rule Includes Proposals to Address Prescription Drug Cost

    The Trump Administration’s effort to address drug prices surfaced unexpectedly in the Department of Health and Human Services (HHS)’s recently issued proposed annual rule that regulates state health insurance markets, including coverage sold through the Affordable Care Act (ACA) marketplaces. The proposal encourages the use of generic drugs over brand-name drugs by both health plans and enrollees […]

    Read More
  • State Health Policy Blog
    As Drug Prices Rise, Oklahoma’s Medicaid Agency Advances Alternative Payment Models

    As Drug Prices Rise, Oklahoma’s Medicaid Agency Advances Alternative Payment Models

    Escalating drug prices are forcing state Medicaid agencies to explore new payment models. According to Burl Beasley, director of Pharmacy Services for Oklahoma’s Medicaid program, older Medicaid payment strategies, such as negotiating enhanced rebates and multi-state purchase agreements, are not keeping pace with rising drug expenditures. Beasley cited the strain prescription drug costs were putting […]

    Read More
    December 17, 2018 | Filed under: Drug Pricing, Front Page, State Health Policy Blog

  • State Health Policy Blog
    States Take Administrative Actions to Curb Medicaid Drug Costs

    States Take Administrative Actions to Curb Medicaid Drug Costs

    During the 2018 legislative session, 28 states passed 45 laws to curb the rising cost of prescription drugs. In addition to legislative solutions, states are taking administrative action to better manage state spending on Medicaid pharmacy benefits. Ohio, West Virginia, and Vermont offer examples of states taking innovative administrative approaches to rein in drug costs. […]

    Read More
  • State Health Policy Blog
    Oklahoma Signs the Nation’s First State Medicaid Value-Based Contracts for Rx Drugs

    Oklahoma Signs the Nation’s First State Medicaid Value-Based Contracts for Rx Drugs

    On the heels of Oklahoma’s first-in-the-nation, value-based purchasing deal to improve adherence to an antipsychotic drug, the state’s Medicaid agency just signed its second value-based contract for a prescription drug used to treat serious bacterial skin infections. While several private insurers have initiated value-based contracting, which links payments to a drug’s effectiveness and outcome, Oklahoma […]

    Read More
  • NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database

    NASHP Issues RFP for Partner to Help States Develop a Drug Cost Transparency Database

    NASHP’s Center for State Rx Drug Pricing seeks a partner to provide technical and strategic expertise to help a workgroup of state officials from California, Nevada, Oregon, Connecticut, and Vermont implement their drug cost transparency laws and help Maine and New Hampshire develop transparency programs as mandated by recent legislation. This work will help all […]

    Read More
    September 18, 2018 | Filed under: Drug Pricing, Featured-Rx, Front Page, Front Page-Rx, Transparency

  • State Health Policy Blog
    As States Take the Lead to Address Drug Costs, Federal Action Follows

    As States Take the Lead to Address Drug Costs, Federal Action Follows

    *Update: On Oct. 10, 2018, President Trump signed two bills designed to increase prescription drug price transparency by prohibiting gag clauses, which prevent pharmacists from disclosing lower-cost drug options to consumers. One bill prohibits gag clauses under Medicare Part D starting in 2020 and the other affects private insurance markets and goes into effect immediately. […]

    Read More
  • State Health Policy Blog
    New NASHP Model Legislation Helps States Bring Transparency to Pharmacy Benefit Managers

    New NASHP Model Legislation Helps States Bring Transparency to Pharmacy Benefit Managers

    The National Academy for State Health Policy (NASHP) has released model legislation to help states shed light on the opaque business practices of pharmacy benefit managers (PBMs). States can use the model bill to require the licensing of PBMs, ban gag clauses that prevent pharmacists from sharing lower-price drug options with consumers, and require more […]

    Read More
  • State Health Policy Blog
    State Lawmaker Will Guzzardi Plots His Next Move to Curb Generic Drug Price Gouging in Illinois

    State Lawmaker Will Guzzardi Plots His Next Move to Curb Generic Drug Price Gouging in Illinois

    Earlier this year, Illinois state Rep. Will Guzzardi proposed an aggressive, anti-price-gouging bill that banned manufacturers from excessively hiking the costs of generic drugs sold to Illinois residents for his first foray into prescription cost control legislation. Guzzardi’s bill was one of a dozen anti-price gouging measures introduced in state legislature this year. The bill […]

    Read More